Oral administration of diosgenin protects optic nerve degeneration in a mouse model of normal-tension glaucoma

• Orally administrated diosgenin distributed in the retina, optic nerve and brain. • Orally administrated diosgenin protected optic nerve loss without affecting intraocular pressure. • Intravitreal injection of diosgenin had no effects on optic nerve loss. In glaucoma, degeneration of visual pathway spread whole brain area, suggesting that restoring the degenerated axons in the whole visual pathway is crucial for vision recovery. Current pharmacological therapies for glaucoma are intraocular pressure-lowering eye drops. However, the contribution of those medications to the recovery of vision loss may be small. Our previous studies revealed that diosgenin has axonal regeneration activity, and distributes in the brain after oral treatment. Therefore, we have hypothesized that the oral administration of diosgenin might better protect the visual pathway in normal-tension glaucoma because of its wide distribution in the brain. Diosgenin was intravitreally or orally administered to optic nerve-crushed mice for 14 days. The number of retinal ganglion cells, optic nerve density, and intraocular pressure were measured. The time course of diosgenin distribution in the retina, optic nerve, and brain after oral administration was quantified using liquid chromatography-mass spectrometry. Intravitreal injection of diosgenin (0.5, 5, 50 μM, twice for14 days) provided no protective effects on the loss of retinal ganglion cells and optic nerves. In contrast, oral administration of diosgenin (1, 10, and 100 mg/kg, daily for 14 days) significantly protected against optic nerve loss but not retinal ganglion cell death. Six hours after oral administration, diosgenin reached the retina, optic nerve and brain at 6 hours. Oral administration of diosgenin protected the optic nerve. Diosgenin is a potential medicine that can be expected to restore the visual field in glaucoma more effectively than local intraocular administration by affecting the brain and eye.

Authors

Institutions

Publication Details

Journal
Phytomedicine Plus
Published
2025-05-22
DOI
https://doi.org/10.1016/j.phyplu.2025.100823
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oral administration of diosgenin protects optic nerve degeneration in a mouse model of normal-tension glaucoma

Chihiro Tohda, Shogo Shibue
Phytomedicine Plus
Glaucoma and retinal disorders
article

Oral administration of diosgenin protects optic nerve degeneration in a mouse model of normal-tension glaucoma

Chihiro Tohda, Shogo Shibue
article en

Abstract

• Orally administrated diosgenin distributed in the retina, optic nerve and brain. • Orally administrated diosgenin protected optic nerve loss without affecting intraocular pressure. • Intravitreal injection of diosgenin had no effects on optic nerve loss. In glaucoma, degeneration of visual pathway spread whole brain area, suggesting that restoring the degenerated axons in the whole visual pathway is crucial for vision recovery. Current pharmacological therapies for glaucoma are intraocular pressure-lowering eye drops. However, the contribution of those medications to the recovery of vision loss may be small. Our previous studies revealed that diosgenin has axonal regeneration activity, and distributes in the brain after oral treatment. Therefore, we have hypothesized that the oral administration of diosgenin might better protect the visual pathway in normal-tension glaucoma because of its wide distribution in the brain. Diosgenin was intravitreally or orally administered to optic nerve-crushed mice for 14 days. The number of retinal ganglion cells, optic nerve density, and intraocular pressure were measured. The time course of diosgenin distribution in the retina, optic nerve, and brain after oral administration was quantified using liquid chromatography-mass spectrometry. Intravitreal injection of diosgenin (0.5, 5, 50 μM, twice for14 days) provided no protective effects on the loss of retinal ganglion cells and optic nerves. In contrast, oral administration of diosgenin (1, 10, and 100 mg/kg, daily for 14 days) significantly protected against optic nerve loss but not retinal ganglion cell death. Six hours after oral administration, diosgenin reached the retina, optic nerve and brain at 6 hours. Oral administration of diosgenin protected the optic nerve. Diosgenin is a potential medicine that can be expected to restore the visual field in glaucoma more effectively than local intraocular administration by affecting the brain and eye.

Phytomedicine PlusVol. 5(3)
University of Toyama (JP)
Openalex Percentile: Top 82%
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.